

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau


(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/163630 A2

- (51) **International Patent Classification:**
C07K 16/30 (2006.01) *A61K 39/395* (2006.01)
- (21) **International Application Number:**
PCT/US2024/013798
- (22) **International Filing Date:**
31 January 2024 (31.01.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/442,389 31 January 2023 (31.01.2023) US
- (71) **Applicant:** **BIGHAT BIOSCIENCES, INC.** [US/US];
1900 Alameda de las Pulgas, San Mateo, California 94403 (US).
- (72) **Inventors:** **DEPRISTO, Mark**; 1900 Alameda de las Pulgas, San Mateo, California 94403 (US). **GREENSIDE, Peyton**; 1900 Alameda de las Pulgas, San Mateo, California 94403 (US). **HENRICI, Ryan**; 1900 Alameda de las Pulgas, San Mateo, California 94403 (US).
- (74) **Agent:** **NG, Jennifer K.**; Orrick, Herrington & Sutcliffe LLP, 2050 Main Street, Suite 1100, Irvine, CA 92614-8255 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** ANTI-CDH17 ANTIBODIES AND USE OF THE SAME



Test Article	Dose (mg/kg)	%Cmax in plasma at 48h	Elimination T _{1/2}
BHB156	5	7.7%	1.8 days
BHB156	20	3.9%	1.6 days
BHB156	50	7.1%	1.8 days
Isotype Control	20	29%	5.5 days

FIG. 14

(57) **Abstract:** Described herein are anti-CDH17 antibodies and use of the same. The anti-CDH17 antibodies provided herein exhibit significantly improved binding affinity after optimization.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*